{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:12 23:20:22.323",
            "Expression": "mesenchymal allo-APZ2-EB",
            "NStudiesAvail": 430639,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "BriefSummary",
                  "BriefTitle",
                  "CentralContactEMail",
                  "CentralContactName",
                  "CentralContactPhone",
                  "CentralContactPhoneExt",
                  "CentralContactRole",
                  "CollaboratorClass",
                  "CollaboratorName",
                  "CompletionDate",
                  "CompletionDateType",
                  "Condition",
                  "ConditionAncestorId",
                  "ConditionAncestorTerm",
                  "ConditionBrowseBranchAbbrev",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "BriefSummary": [
                              "The aim of this clinical trial is to investigate the efficacy (by monitoring overall improvement of EB symptoms) and safety (by monitoring adverse events) of three doses of allo-APZ2-EB administered intravenously to patients with recessive dystrophic epidermolysis bullosa (RDEB)."
                        ],
                        "BriefTitle": [
                              "Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [
                              "INDUSTRY",
                              "OTHER",
                              "INDUSTRY"
                        ],
                        "CollaboratorName": [
                              "FGK Clinical Research GmbH",
                              "Granzer Regulatory Consulting & Services",
                              "Ticeba GmbH"
                        ],
                        "CompletionDate": [
                              "November 26, 2021"
                        ],
                        "CompletionDateType": [
                              "Actual"
                        ],
                        "Condition": [
                              "Recessive Dystrophic Epidermolysis Bullosa"
                        ],
                        "ConditionAncestorId": [
                              "D000012868",
                              "D000000013",
                              "D000012873",
                              "D000030342",
                              "D000012871",
                              "D000012872",
                              "D000003095",
                              "D000003240"
                        ],
                        "ConditionAncestorTerm": [
                              "Skin Abnormalities",
                              "Congenital Abnormalities",
                              "Skin Diseases, Genetic",
                              "Genetic Diseases, Inborn",
                              "Skin Diseases",
                              "Skin Diseases, Vesiculobullous",
                              "Collagen Diseases",
                              "Connective Tissue Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC16",
                              "All",
                              "BC17",
                              "BC05",
                              "Rare"
                        ],
                        "NCTId": [
                              "NCT03529877"
                        ]
                  },
                  {
                        "Rank": 2,
                        "BriefSummary": [
                              "The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with JEB and to RDEB subjects < 1 year."
                        ],
                        "BriefTitle": [
                              "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [],
                        "CollaboratorName": [],
                        "CompletionDate": [
                              "December 2025"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Epidermolysis Bullosa"
                        ],
                        "ConditionAncestorId": [
                              "D000012868",
                              "D000000013",
                              "D000012873",
                              "D000030342",
                              "D000012871",
                              "D000012872"
                        ],
                        "ConditionAncestorTerm": [
                              "Skin Abnormalities",
                              "Congenital Abnormalities",
                              "Skin Diseases, Genetic",
                              "Genetic Diseases, Inborn",
                              "Skin Diseases",
                              "Skin Diseases, Vesiculobullous"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC16",
                              "BC17",
                              "All",
                              "Rare"
                        ],
                        "NCTId": [
                              "NCT05464381"
                        ]
                  }
            ]
      }
}